Results 241 to 250 of about 193,702 (280)

Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison. [PDF]

J Comp Eff Res
Bauer T, Abrahami D, Polli A, Chu H, Ramachandran P, Chandler C, Tan M, Truscott J, Mazieres J, Garcia CA.   +9 more
europepmc   +1 more source

Complete lymph node dissection versus selective lymph node extirpation in melanoma patients with nodal macrometastasis and adjuvant systemic therapy

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Complete lymph node dissection (CLND) is the standard of care in patients with regional nodal melanoma macrometastasis. However, evidence on surgical procedures in the era of adjuvant systemic therapies is lacking. Patients and Methods This retrospective multi‐center study included stage IIIB–D melanoma patients with ...
Kristine E. Mayer, Jessica C. Hassel, Jannik Sambale, Michael Erdmann, Mihaela‐Anca Sindrilaru, Julia Oberschmied, Alexander Thiem, Dirk Tomsitz, Jana Knuever, Max Schlaak, Carola Berking, Christian Posch, Tilo Biedermann, Oana‐Diana Persa   +13 more
wiley   +1 more source

Alectinib versus crizotinib as the first-line treatment in patients with advanced ALK-positive non-small cell lung cancer: a Chinese real-world cohort study. [PDF]

Transl Lung Cancer Res
Zhang H, Wu Z, Lu T, Zhang H, Li J, Zhang D, Yu S, Guo X, Feng X, Liu J, Shi Y, Gao X, Liu X, Chen M, Zhao J, Zhong W, Hu Y, Xu Y, Wang M.   +18 more
europepmc   +1 more source

Applying Progress Testing to Undergraduate Periodontal Courses—A First Evaluation After 2 Years of Use in a German University

European Journal of Dental Education, EarlyView.
ABSTRACT Background The Progress Test in Periodontology (PTP) has been implemented at Kiel University to gain an impression of students' learning process in this specific subdiscipline of periodontology within the dental curriculum. Methods The PTP has been designed following internationally established standards and has been adapted into the context ...
Anna Louisa Kollster, Miriam Cyris, Jonas Conrad, Mohamed Mekhemar, Christof E. Dörfer, Christian Graetz   +5 more
wiley   +1 more source

Molecular Mechanisms and Treatment Strategies of ALK-Positive Lung Cancer: A Beginner's Guide for Patients, Their Families and Carers. [PDF]

Thorac Cancer
Klenova E.
europepmc   +1 more source

Exploring the Disease Duration of Urticaria and Associated Determinants in Primary Care

Clinical &Experimental Allergy, EarlyView.
R. Soegiharto, B. J. Hengevelt, N. Boekema‐Bakker, I. A. M. Groenewegen, A. C. Knulst, J. M. P. A. Van den Reek, H. Röckmann   +6 more
wiley   +1 more source

Alterations of bone proteins in medication‐related osteonecrosis of the jaw

European Journal of Oral Sciences, Volume 133, Issue 2, April 2025.
Abstract Changes in the protein expression pattern of osteoblastic lineage cells from the alveolar bone (OLAB) during medication‐related osteonecrosis of the jaw (MRONJ) have rarely been investigated. This lack of information is partly because of the limited availability of healthy samples and the lack of human alveolar bone cell lines for research ...
Andrea Schubert, Phillipp Brockmeyer, Philipp Kauffmann, Jan Wiegel, Florian Lautenbacher, Nicolai Miosge, Boris Schminke   +6 more
wiley   +1 more source

First Report of Response to Tarlatamab in a Patient With Histologic-Transformed SCLC From <i>ALK</i>-Rearranged NSCLC: Case Report. [PDF]

JTO Clin Res Rep
Wang K, Taslic CA, de Groot P, Parma MA, Paula AG, Caranto M, Shah K, Bose M, Ruoff C, Karacosta LG, Byers LA, Gay CM, Zhang J, Heymach JV, Zhang B.   +14 more
europepmc   +1 more source

Radiotherapy for large ruptured hemorrhagic axillary lymph node metastasis from anaplastic lymphoma kinase-positive lung adenocarcinoma: A case report and review of literature. [PDF]

World J Clin Oncol
Li ZM, Wang YC, Wang KY, Xie NJ, Zhou J, Chang XN, Chen Q, Wang G, Zhang S, Zhou R.   +9 more
europepmc   +1 more source

Real-world first-line outcomes of alectinib and brigatinib in anaplastic lymphoma kinase-positive non-small cell lung cancer: a nationwide South Korean cohort study using the health insurance review and assessment data. [PDF]

Transl Lung Cancer Res
Kim HJ, Lee EA, Park JH, Lee HW.
europepmc   +1 more source